Report Company Directory

Agilysys Inc.

• InsiderInsights.com Daily Ratings Report: February 3, 2026 by InsiderInsights.com
• Today at 1 p.m. ET: Fear, Not Fundamentals – The Sentiment Problem and Why Software Is So Challenging Right Now by William Blair
• Fear, Not Fundamentals: the Sentiment Problem and Why Software Is So Challenging Right Now by William Blair
• Conservative Guidance May Fall Short of Loftier Expectations, but Marriott and Pipeline Commentary Leaves Us Encouraged by William Blair
• Tracking Restaurant Engagement, Digital Trends, and Brand Affinity: December 2025 by William Blair
• Claude Cowork the Latest Boogeyman in Software; Selloff Seems Overdone by William Blair
• Presentation Slides: Technology, Media, and Communications 2026 Outlook and Top Stock Picks by William Blair
• Technology, Media, and Communications Outlook and Top Stock Recommendations for 2026 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair

Agilyx

• Agilyx (Buy): Recommendation and target price withdrawn by Carnegie Investment Bank AB (publ)
• Agilyx (Buy): Taking on the yellow jersey by Carnegie Investment Bank AB (publ)
• Agilyx (Buy, TP: NOK37.00) - CCC construction in focus by DnB Markets
• Agilyx (Buy, TP: NOK38.00) - Firming up its second CCC by DnB Markets
• Agilyx (Buy, TP: NOK40.00) - Progressing as planned by DnB Markets
• Agilyx - Initiation of coverage - Completing the plastics cycle by DnB Markets
• Agilyx - Commissioned Research: Flash Comment: First Cyclyx Circularity Centre FID reached, with approval to move forward to construction by Nordea
• Agilyx - Commissioned Research: Flash Comment: L9M revenue down y/y, but continued improvement in gross profit contribution and business model repositioning in place by Nordea
• Agilyx - Commissioned Research: Flash Comment: Preparing for a new phase of growth by Nordea
• Agilyx - Commissioned research: Flash Comment: Several key operational and organizational announcements released – key milestones for next steps by Nordea

AGIO PAPER & INDUSTRIES LTD

Agios Pharmaceuticals Inc.

• Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET by GlobeNewsWire
• Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth by GlobeNewsWire
• Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 by GlobeNewsWire
• U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia by GlobeNewsWire
• Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia by GlobeNewsWire
• Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease by GlobeNewsWire
• Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition by GlobeNewsWire
• Agios Reports Third Quarter 2025 Financial Results and Provides Business Update by GlobeNewsWire
• Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia by GlobeNewsWire
• Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET by GlobeNewsWire

AGIUM INVESTIUM SIMCAV SA